AstraZeneca‘s IMFINZI® (durvalumab) has gained FDA approval for use in adult patients with muscle-invasive bladder cancer ...

After Meritain rejected the initial immunotherapy drug, Imfinzi, Brian applied for coverage of a second, similar drug, Keytruda. That, too, was denied. The McNamaras appealed the rulings.

Brian McNamara has a shot at beating his aggressive cancer, but his Aetna subsidiary insurance company doesn't want to pay ...